Immunitas Therapeutics Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting On April 17, 2026, Immunitas Therapeutics announced it will present clinical data …
Tag: